Shopping Cart 0
Cart Subtotal
USD 0

Polycystic Ovarian Syndrome Treatment Market by Drug Class (Insulin Sensitizing Agent, Oral Contraceptive, Antiandrogens, Anti-Obesity Drugs, and Others), and Distribution Channel (Hospital Pharmacy, Drug Store & Retail Pharmacy, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019-2026

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 5370

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 8995

Details

The global polycystic ovarian syndrome treatment market was valued at USD 2,902 million in 2018, and is projected to reach USD 4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.
 
Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, medications are used to regulate menstrual cycle and manage symptoms of PCOS.
 
The polycystic ovarian syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in prevalence of PCOS, rise in awareness among the patient population about PCOS, and increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth.
 
The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers . Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
 
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Class
Insulin Sensitizing Agent
Oral Contraceptive
Antiandrogens
Anti-Obesity Drugs
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Allergan plc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Johnson and Johnson
Mylan N.V.
Novartis AG
Pfizer Inc.
SANOFI
Teva Pharmaceutical Industries
 
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Merck KGaA
Ferring BV
 
 
READ MORE

Table Of Content

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Key Findings

 

2.2.1. Top Investment Pockets

2.2.2. Market Player Positioning, 2018

 

2.3. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Forces Shaping Polycystic Ovarian Syndrome Treatment Industry/Market

 

3.2.1. Moderate Power of Suppliers

3.2.2. High Threat of New Entrants

3.2.3. High Threat of Substitution

3.2.4. Moderate Competitive Rivalry

3.2.5. Moderate Bargaining Power of Buyers

 

3.3. Market Dynamics

 

3.3.1. Drivers

 

3.3.1.1. Increase In Prevalence of Pcos

3.3.1.2. Increase In Number of Pipeline Drugs

3.3.1.3. Surge In Healthcare Expenditure Worldwide

 

3.3.2. Restraint

 

3.3.2.1. Lack of Approved Therapeutics For Treatment of Pcos

 

3.3.3. Opportunities

 

3.3.3.1. Growth Opportunities In Emerging Markets

3.3.3.2. Higher Number of Unmet Needs For Treatment of Pcos

 

3.3.4. Impact Analysis

 

Chapter 4: Polycystic Ovarian Syndrome Treatment Market, By Drug Class

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Insulin Sensitizing Agent

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Oral Contraceptive

 

4.3.1. Key Market Trends And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis, By Country

 

4.4. Antiandrogens

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis, By Country

 

4.5. Anti-Obesity Drugs

 

4.5.1. Key Market Trends And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis, By Country

 

4.6. Others

 

4.6.1. Key Market Trends And Opportunities

4.6.2. Market Size And Forecast, By Region

4.6.3. Market Analysis, By Country

 

Chapter 5: Polycystic Ovarian Syndrome Treatment Market, By End User

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Hospitals Pharmacies

 

5.2.1. Market Size And Forecast

5.2.2. Market Analysis, By Country

 

5.3. Drug Stores And Retail Pharmacies

 

5.3.1. Market Size And Forecast

5.3.2. Market Analysis, By Country

 

5.4. Online Pharmacies

 

5.4.1. Market Size And Forecast

5.4.2. Market Analysis, By Country

 

Chapter 6: Polycystic Ovarian Syndrome Treatment Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends, Growth Factors, And Opportunities

6.2.2. Market Size And Forecast, By Country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.2.2.1.2. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.2.2.2.2. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.2.2.3.2. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.2.3. North America Market Size And Forecast, By Drug Class

6.2.4. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3. Europe

 

6.3.1. Key Market Trends, Growth Factors, And Opportunities

6.3.2. Market Size And Forecast, By Country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.1.2. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.2. France

 

6.3.2.2.1. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.2.2. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.3. Uk

 

6.3.2.3.1. Uk Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.3.2. Uk Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.4.2. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.5.2. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.6.2. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.3. Europe Market Size And Forecast, By Drug Class

6.3.4. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4. Asia-Pacific

 

6.4.1. Key Market Trends, Growth Factors, And Opportunities

6.4.2. Market Size And Forecast, By Country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.1.2. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.2. China

 

6.4.2.2.1. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.2.2. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.3.2. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.4. India

 

6.4.2.4.1. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.4.2. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.5.2. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.6.2. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class

6.4.4. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5. Lamea

 

6.5.1. Key Market Trends, Growth Factors, And Opportunities

6.5.2. Market Size And Forecast, By Country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.1.2. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.2.2. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.3.2. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.2.4. Rest of Lamea

 

6.5.2.4.1. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.4.2. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.3. Lamea Market Size And Forecast, By Drug Class

6.5.4. Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

Chapter 7: Company Profiles

 

7.1. Allergan Plc

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Astrazeneca Plc

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Bayer Ag.

 

7.3.1. Company Overview

7.3.2. Operating Business Segments

7.3.3. Product Portfolio

7.3.4. Business Performance

 

7.4. Bristol-Myers Squibb Company

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. Johnson And Johnson

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Mylan N.V

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Novartis Ag

 

7.7.1. Company Overview

7.7.2. Company Snapshot

7.7.3. Operating Business Segments

7.7.4. Product Portfolio

7.7.5. Business Performance

 

7.8. Pfizer Inc.

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Sanofi

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

 

7.10. Teva Pharmaceutical Industries

 

7.10.1. Company Overview

7.10.2. Operating Business Segments

7.10.3. Product Portfolio

7.10.4. Business Performance

7.10.5. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Top Investment Pockets

Figure 02. Market Player Positioning, 2018

Figure 03. Global Polycystic Ovarian Syndrome Treatment Market Segmentation

Figure 04. Impact Analysis

Figure 05. Comparative Analysis of Insulin Sensitizing Agent Market, By Country, 2018 & 2026 (USD Million)

Figure 06. Comparative Analysis of Oral Contraceptive Market, By Country, 2018 & 2026 (USD Million)

Figure 07. Comparative Analysis of Antiandrogens Market, By Country, 2018 & 2026 (USD Million)

Figure 08. Comparative Analysis of Anti-Obesity Drugs Market, By Country, 2018 & 2026 (USD Million)

Figure 09. Comparative Analysis of Others Market, By Country, 2018 & 2026 (USD Million)

Figure 10. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Hospitals Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Online Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 13. U.S. Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 14. Canada Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 15. Mexico Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 16. Germany Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 17. France Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 18. Uk Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 19. Italy Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 20. Spain Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 21. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 22. Japan Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 23. China Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 24. Australia Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 25. India Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 26. South Korea Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 27. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 28. Brzil Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 29. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 30. South Africa Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 31. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 32. Allergan: Net Sales, 2016-2018 (USD Million)

Figure 33. Allergan: Revenue Share By Region, 2018(%)

Figure 34. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 35. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 36. Bayer: Net Sales, 2016-2018 (USD Million)

Figure 37. Bayer.: Revenue Share By Segment, 2018 (%)

Figure 38. Bayer.: Revenue Share By Region, 2018(%)

Figure 39. Bms: Net Sales, 2016-2018 (USD Million)

Figure 40. Bms: Revenue Share By Region, 2018(%)

Figure 41. J&J: Net Sales, 2016-2018 (USD Million)

Figure 42. J&J: Revenue Share By Segment, 2018 (%)

Figure 43. J&J: Revenue Share By Region, 2018(%)

Figure 44. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 45. Mylan: Revenue Share By Geography, 2018 (%)

Figure 46. Novartis: Net Sales, 2016-2018 (USD Million)

Figure 47. Novartis: Revenue Share By Segment, 2018 (%)

Figure 48. Novartis: Revenue Share By Region, 2018(%)

Figure 49. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 50. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 51. Pfizer: Revenue Share By Region, 2018(%)

Figure 52. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 53. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 54. Sanofi: Revenue Share By Region, 2018(%)

Figure 55. Teva Pharmaceutical Industries: Net Sales, 2016-2018 (USD Million)

Figure 56. Teva Pharmaceutical Industries: Revenue Share By Segments 2018 (USD Million)


List Of Table

List of Tables

 

Table 01. Global Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026 (USD Million)

Table 02. Insulin Sensitizing Agent Market, By Region, 2018-2026 (USD Million)

Table 03. Oral Contraceptive Market, By Region, 2018-2026 (USD Million)

Table 04. Antiandrogens Market, By Region, 2018-2026 (USD Million)

Table 05. Anti-Obesity Drugs Market, By Region, 2018-2026 (USD Million)

Table 06. Others Market, By Region, 2018-2026 (USD Million)

Table 07. Global Polycystic Ovarian Syndrome Treatment Market, By End User, 2018-2026 (USD Million)

Table 08. Polycystic Ovarian Syndrome Treatment Market For Hospitals Pharmacies, By Region, 2018-2026 (USD Million)

Table 09. Polycystic Ovarian Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Region, 2018-2026 (USD Million)

Table 10. Polycystic Ovarian Syndrome Treatment Market For Online Pharmacies, By Region, 2018-2026 (USD Million)

Table 11. Polycystic Ovarian Syndrome Treatment Market Revenue, By Region, 2018-2026 (USD Million)

Table 12. North America Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 13. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 14. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 15. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 16. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 17. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 18. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 19. North America Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 20. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 21. Europe Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 22. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 23. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 24. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 25. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 26. Uk Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 27. Uk Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 28. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 29. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 30. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 31. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 32. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 33. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 34. Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 35. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 36. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 37. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 38. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 39. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 40. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 41. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 42. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 43. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 44. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 45. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 46. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 47. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 48. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 49. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 50. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 51. Lamea Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 52. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 53. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 54. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 55. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 56. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 57. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 58. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 59. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 60. Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 61. Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 62. Allergan: Company Snapshot

Table 63. Allergan: Operating Segments

Table 64. Allergan: Product Portfolio

Table 65. Astrazeneca: Company Snapshot

Table 66. Astrazeneca: Product Segments

Table 67. Astrazeneca: Product Portfolio

Table 68. Bayer.: Company Snapshot

Table 69. Bayer.: Operating Segments

Table 70. Bayer.: Product Portfolio

Table 71. Bms: Company Snapshot

Table 72. Bms: Operating Segments

Table 73. Bms: Product Portfolio

Table 74. J&J: Company Snapshot

Table 75. J&J: Operating Segments

Table 76. J&J: Product Portfolio

Table 77. Mylan: Company Snapshot

Table 78. Mylan: Operating Segments

Table 79. Mylan: Product Portfolio

Table 80. Novartis: Company Snapshot

Table 81. Novartis: Operating Segments

Table 82. Novartis: Product Portfolio

Table 83. Pfizer: Company Snapshot

Table 84. Pfizer: Operating Segments

Table 85. Pfizer: Product Portfolio

Table 86. Sanofi: Company Snapshot

Table 87. Sanofi: Operating Segments

Table 88. Sanofi: Product Portfolio

Table 89. Teva: Company Snapshot

Table 90. Teva: Product Portfolio

Licence Rights

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

Allergan plc., AstraZeneca plc., Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, and Teva Pharmaceutical Industries.

Company Profile

Company Profile Title

The global polycystic ovarian syndrome treatment market was valued at USD 2,902 million in 2018, and is projected to reach USD 4,184 million by 2026, registering a CAGR of 4.7% from 2019 to 2026.
 
Polycystic ovary syndrome or PCOS is a hormonal disorder that is common among women of childbearing age. PCOS causes infrequent or prolonged menstrual cycle or excess male hormone levels. Presently, there is no cure for PCOS, however, medications are used to regulate menstrual cycle and manage symptoms of PCOS.
 
The polycystic ovarian syndrome treatment market is expected to experience a significant growth during the forecast period, owing to increase in prevalence of PCOS, rise in awareness among the patient population about PCOS, and increase in popularity of combination therapy drives the market growth. In addition, easy accessibility to PCOS therapeutics, rise in demand for PCOS medication, and technological advancements for detection of PCOS influence the market growth. However, lack of approved therapeutics and unknown etiology and pathophysiology of PCOS is anticipated to hamper the market growth.
 
The global polycystic ovarian syndrome treatment market is segmented on the basis of drug class, distribution channel, and region. Based on drug class, it is classified as insulin sensitizing agent, oral contraceptive, antiandrogens, anti-obesity drugs, and others. According to distribution channel, it is categorized as hospital pharmacies, drug stores & retail pharmacies, and online providers . Region wise, it is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
 
 
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
 
KEY MARKET SEGMENTS
By Drug Class
Insulin Sensitizing Agent
Oral Contraceptive
Antiandrogens
Anti-Obesity Drugs
Others
By Distribution Channel
Hospital Pharmacies
Drug Stores & Retail Pharmacies
Online Providers
By Region
 
North America
o U.S.
o Canada
o Mexico
Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
Asia-Pacific
o Japan
o China
o Australia
o India
o South Korea
o Rest of Asia-Pacific
LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
Allergan plc.
AstraZeneca plc
Bayer AG
Bristol-Myers Squibb Company
Johnson and Johnson
Mylan N.V.
Novartis AG
Pfizer Inc.
SANOFI
Teva Pharmaceutical Industries
 
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
Merck KGaA
Ferring BV
 
 
READ MORE

Scope

Chapter 1: Introduction

 

1.1. Report Description

1.2. Key Benefits For Stakeholders

1.3. Key Market Segments

 

1.3.1. List of Key Players Profiled In The Report

 

1.4. Research Methodology

 

1.4.1. Secondary Research

1.4.2. Primary Research

1.4.3. Analyst Tools And Models

 

Chapter 2: Executive Summary

 

2.1. Key Findings of The Study

2.2. Key Findings

 

2.2.1. Top Investment Pockets

2.2.2. Market Player Positioning, 2018

 

2.3. Cxo Perspective

 

Chapter 3: Market Overview

 

3.1. Market Definition And Scope

3.2. Key Forces Shaping Polycystic Ovarian Syndrome Treatment Industry/Market

 

3.2.1. Moderate Power of Suppliers

3.2.2. High Threat of New Entrants

3.2.3. High Threat of Substitution

3.2.4. Moderate Competitive Rivalry

3.2.5. Moderate Bargaining Power of Buyers

 

3.3. Market Dynamics

 

3.3.1. Drivers

 

3.3.1.1. Increase In Prevalence of Pcos

3.3.1.2. Increase In Number of Pipeline Drugs

3.3.1.3. Surge In Healthcare Expenditure Worldwide

 

3.3.2. Restraint

 

3.3.2.1. Lack of Approved Therapeutics For Treatment of Pcos

 

3.3.3. Opportunities

 

3.3.3.1. Growth Opportunities In Emerging Markets

3.3.3.2. Higher Number of Unmet Needs For Treatment of Pcos

 

3.3.4. Impact Analysis

 

Chapter 4: Polycystic Ovarian Syndrome Treatment Market, By Drug Class

 

4.1. Overview

 

4.1.1. Market Size And Forecast

 

4.2. Insulin Sensitizing Agent

 

4.2.1. Key Market Trends And Opportunities

4.2.2. Market Size And Forecast, By Region

4.2.3. Market Analysis, By Country

 

4.3. Oral Contraceptive

 

4.3.1. Key Market Trends And Opportunities

4.3.2. Market Size And Forecast, By Region

4.3.3. Market Analysis, By Country

 

4.4. Antiandrogens

 

4.4.1. Key Market Trends And Opportunities

4.4.2. Market Size And Forecast, By Region

4.4.3. Market Analysis, By Country

 

4.5. Anti-Obesity Drugs

 

4.5.1. Key Market Trends And Opportunities

4.5.2. Market Size And Forecast, By Region

4.5.3. Market Analysis, By Country

 

4.6. Others

 

4.6.1. Key Market Trends And Opportunities

4.6.2. Market Size And Forecast, By Region

4.6.3. Market Analysis, By Country

 

Chapter 5: Polycystic Ovarian Syndrome Treatment Market, By End User

 

5.1. Overview

 

5.1.1. Market Size And Forecast

 

5.2. Hospitals Pharmacies

 

5.2.1. Market Size And Forecast

5.2.2. Market Analysis, By Country

 

5.3. Drug Stores And Retail Pharmacies

 

5.3.1. Market Size And Forecast

5.3.2. Market Analysis, By Country

 

5.4. Online Pharmacies

 

5.4.1. Market Size And Forecast

5.4.2. Market Analysis, By Country

 

Chapter 6: Polycystic Ovarian Syndrome Treatment Market, By Region

 

6.1. Overview

 

6.1.1. Market Size And Forecast

 

6.2. North America

 

6.2.1. Key Market Trends, Growth Factors, And Opportunities

6.2.2. Market Size And Forecast, By Country

 

6.2.2.1. U.S.

 

6.2.2.1.1. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.2.2.1.2. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.2.2.2. Canada

 

6.2.2.2.1. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.2.2.2.2. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.2.2.3. Mexico

 

6.2.2.3.1. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.2.2.3.2. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.2.3. North America Market Size And Forecast, By Drug Class

6.2.4. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3. Europe

 

6.3.1. Key Market Trends, Growth Factors, And Opportunities

6.3.2. Market Size And Forecast, By Country

 

6.3.2.1. Germany

 

6.3.2.1.1. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.1.2. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.2. France

 

6.3.2.2.1. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.2.2. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.3. Uk

 

6.3.2.3.1. Uk Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.3.2. Uk Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.4. Italy

 

6.3.2.4.1. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.4.2. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.5. Spain

 

6.3.2.5.1. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.5.2. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.2.6. Rest of Europe

 

6.3.2.6.1. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.3.2.6.2. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.3.3. Europe Market Size And Forecast, By Drug Class

6.3.4. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4. Asia-Pacific

 

6.4.1. Key Market Trends, Growth Factors, And Opportunities

6.4.2. Market Size And Forecast, By Country

 

6.4.2.1. Japan

 

6.4.2.1.1. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.1.2. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.2. China

 

6.4.2.2.1. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.2.2. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.3. Australia

 

6.4.2.3.1. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.3.2. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.4. India

 

6.4.2.4.1. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.4.2. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.5. South Korea

 

6.4.2.5.1. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.5.2. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.2.6. Rest of Asia-Pacific

 

6.4.2.6.1. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.4.2.6.2. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class

6.4.4. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5. Lamea

 

6.5.1. Key Market Trends, Growth Factors, And Opportunities

6.5.2. Market Size And Forecast, By Country

 

6.5.2.1. Brazil

 

6.5.2.1.1. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.1.2. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.2.2. Saudi Arabia

 

6.5.2.2.1. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.2.2. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.2.3. South Africa

 

6.5.2.3.1. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.3.2. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.2.4. Rest of Lamea

 

6.5.2.4.1. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class

6.5.2.4.2. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

6.5.3. Lamea Market Size And Forecast, By Drug Class

6.5.4. Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel

 

Chapter 7: Company Profiles

 

7.1. Allergan Plc

 

7.1.1. Company Overview

7.1.2. Company Snapshot

7.1.3. Operating Business Segments

7.1.4. Product Portfolio

7.1.5. Business Performance

 

7.2. Astrazeneca Plc

 

7.2.1. Company Overview

7.2.2. Company Snapshot

7.2.3. Operating Business Segments

7.2.4. Product Portfolio

7.2.5. Business Performance

 

7.3. Bayer Ag.

 

7.3.1. Company Overview

7.3.2. Operating Business Segments

7.3.3. Product Portfolio

7.3.4. Business Performance

 

7.4. Bristol-Myers Squibb Company

 

7.4.1. Company Overview

7.4.2. Company Snapshot

7.4.3. Operating Business Segments

7.4.4. Product Portfolio

7.4.5. Business Performance

 

7.5. Johnson And Johnson

 

7.5.1. Company Overview

7.5.2. Company Snapshot

7.5.3. Operating Business Segments

7.5.4. Product Portfolio

7.5.5. Business Performance

 

7.6. Mylan N.V

 

7.6.1. Company Overview

7.6.2. Company Snapshot

7.6.3. Operating Business Segments

7.6.4. Product Portfolio

7.6.5. Business Performance

 

7.7. Novartis Ag

 

7.7.1. Company Overview

7.7.2. Company Snapshot

7.7.3. Operating Business Segments

7.7.4. Product Portfolio

7.7.5. Business Performance

 

7.8. Pfizer Inc.

 

7.8.1. Company Overview

7.8.2. Company Snapshot

7.8.3. Operating Business Segments

7.8.4. Product Portfolio

7.8.5. Business Performance

 

7.9. Sanofi

 

7.9.1. Company Overview

7.9.2. Company Snapshot

7.9.3. Operating Business Segments

7.9.4. Product Portfolio

7.9.5. Business Performance

 

7.10. Teva Pharmaceutical Industries

 

7.10.1. Company Overview

7.10.2. Operating Business Segments

7.10.3. Product Portfolio

7.10.4. Business Performance

7.10.5. Key Strategic Moves And Developments


List Of Figure

List of Figures

 

Figure 01. Top Investment Pockets

Figure 02. Market Player Positioning, 2018

Figure 03. Global Polycystic Ovarian Syndrome Treatment Market Segmentation

Figure 04. Impact Analysis

Figure 05. Comparative Analysis of Insulin Sensitizing Agent Market, By Country, 2018 & 2026 (USD Million)

Figure 06. Comparative Analysis of Oral Contraceptive Market, By Country, 2018 & 2026 (USD Million)

Figure 07. Comparative Analysis of Antiandrogens Market, By Country, 2018 & 2026 (USD Million)

Figure 08. Comparative Analysis of Anti-Obesity Drugs Market, By Country, 2018 & 2026 (USD Million)

Figure 09. Comparative Analysis of Others Market, By Country, 2018 & 2026 (USD Million)

Figure 10. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Hospitals Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 11. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 12. Comparative Analysis of Polycystic Ovarian Syndrome Treatment Market For Online Pharmacies, By Country, 2018 & 2026 (USD Million)

Figure 13. U.S. Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 14. Canada Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 15. Mexico Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 16. Germany Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 17. France Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 18. Uk Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 19. Italy Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 20. Spain Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 21. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 22. Japan Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 23. China Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 24. Australia Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 25. India Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 26. South Korea Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 27. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 28. Brzil Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 29. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 30. South Africa Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 31. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, 2018-2026 (USD Million)

Figure 32. Allergan: Net Sales, 2016-2018 (USD Million)

Figure 33. Allergan: Revenue Share By Region, 2018(%)

Figure 34. Astrazeneca: Net Sales, 2016-2018 (USD Million)

Figure 35. Astrazeneca: Revenue Share By Region, 2018(%)

Figure 36. Bayer: Net Sales, 2016-2018 (USD Million)

Figure 37. Bayer.: Revenue Share By Segment, 2018 (%)

Figure 38. Bayer.: Revenue Share By Region, 2018(%)

Figure 39. Bms: Net Sales, 2016-2018 (USD Million)

Figure 40. Bms: Revenue Share By Region, 2018(%)

Figure 41. J&J: Net Sales, 2016-2018 (USD Million)

Figure 42. J&J: Revenue Share By Segment, 2018 (%)

Figure 43. J&J: Revenue Share By Region, 2018(%)

Figure 44. Mylan: Net Sales, 2016-2018 (USD Million)

Figure 45. Mylan: Revenue Share By Geography, 2018 (%)

Figure 46. Novartis: Net Sales, 2016-2018 (USD Million)

Figure 47. Novartis: Revenue Share By Segment, 2018 (%)

Figure 48. Novartis: Revenue Share By Region, 2018(%)

Figure 49. Pfizer: Net Sales, 2016-2018 (USD Million)

Figure 50. Pfizer: Revenue Share By Segment, 2018 (%)

Figure 51. Pfizer: Revenue Share By Region, 2018(%)

Figure 52. Sanofi: Net Sales, 2016-2018 (USD Million)

Figure 53. Sanofi: Revenue Share By Segment, 2018 (%)

Figure 54. Sanofi: Revenue Share By Region, 2018(%)

Figure 55. Teva Pharmaceutical Industries: Net Sales, 2016-2018 (USD Million)

Figure 56. Teva Pharmaceutical Industries: Revenue Share By Segments 2018 (USD Million)


List Of Table

List of Tables

 

Table 01. Global Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026 (USD Million)

Table 02. Insulin Sensitizing Agent Market, By Region, 2018-2026 (USD Million)

Table 03. Oral Contraceptive Market, By Region, 2018-2026 (USD Million)

Table 04. Antiandrogens Market, By Region, 2018-2026 (USD Million)

Table 05. Anti-Obesity Drugs Market, By Region, 2018-2026 (USD Million)

Table 06. Others Market, By Region, 2018-2026 (USD Million)

Table 07. Global Polycystic Ovarian Syndrome Treatment Market, By End User, 2018-2026 (USD Million)

Table 08. Polycystic Ovarian Syndrome Treatment Market For Hospitals Pharmacies, By Region, 2018-2026 (USD Million)

Table 09. Polycystic Ovarian Syndrome Treatment Market For Drug Stores And Retail Pharmacies, By Region, 2018-2026 (USD Million)

Table 10. Polycystic Ovarian Syndrome Treatment Market For Online Pharmacies, By Region, 2018-2026 (USD Million)

Table 11. Polycystic Ovarian Syndrome Treatment Market Revenue, By Region, 2018-2026 (USD Million)

Table 12. North America Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 13. U.S. Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 14. U.S. Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 15. Canada Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 16. Canada Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 17. Mexico Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 18. Mexico Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 19. North America Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 20. North America Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 21. Europe Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 22. Germany Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 23. Germany Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 24. France Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 25. France Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 26. Uk Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 27. Uk Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 28. Italy Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 29. Italy Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 30. Spain Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 31. Spain Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 32. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 33. Rest of Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 34. Europe Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 35. Europe Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 36. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 37. Japan Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 38. Japan Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 39. China Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 40. China Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 41. Australia Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 42. Australia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 43. India Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 44. India Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 45. South Korea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 46. South Korea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 47. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 48. Rest of Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 49. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 50. Asia-Pacific Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 51. Lamea Polycystic Ovarian Syndrome Treatment Market, By Country, 2018-2026 (USD Million)

Table 52. Brazil Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 53. Brazil Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 54. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 55. Saudi Arabia Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 56. South Africa Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 57. South Africa Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 58. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 59. Rest of Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 60. Lamea Polycystic Ovarian Syndrome Treatment Market, By Drug Class, 2018-2026

Table 61. Lamea Polycystic Ovarian Syndrome Treatment Market, By Distribution Channel, 2018-2026

Table 62. Allergan: Company Snapshot

Table 63. Allergan: Operating Segments

Table 64. Allergan: Product Portfolio

Table 65. Astrazeneca: Company Snapshot

Table 66. Astrazeneca: Product Segments

Table 67. Astrazeneca: Product Portfolio

Table 68. Bayer.: Company Snapshot

Table 69. Bayer.: Operating Segments

Table 70. Bayer.: Product Portfolio

Table 71. Bms: Company Snapshot

Table 72. Bms: Operating Segments

Table 73. Bms: Product Portfolio

Table 74. J&J: Company Snapshot

Table 75. J&J: Operating Segments

Table 76. J&J: Product Portfolio

Table 77. Mylan: Company Snapshot

Table 78. Mylan: Operating Segments

Table 79. Mylan: Product Portfolio

Table 80. Novartis: Company Snapshot

Table 81. Novartis: Operating Segments

Table 82. Novartis: Product Portfolio

Table 83. Pfizer: Company Snapshot

Table 84. Pfizer: Operating Segments

Table 85. Pfizer: Product Portfolio

Table 86. Sanofi: Company Snapshot

Table 87. Sanofi: Operating Segments

Table 88. Sanofi: Product Portfolio

Table 89. Teva: Company Snapshot

Table 90. Teva: Product Portfolio

Single-User license:

This  grants one non-exclusive, non-transferable machine-readable license for the report either electronically or online. The right to store, display, use, or stockpile the report is restricted to only ONE authorized computer. For obtaining a single user license, ONLY an individual ("you") for individual use is entitled for using the product or as mentioned in the License Terms. Any individual representing an organization is refrained from accessing the products/services of AMR or as stated in the License Terms; any breach of which shall lead to violation of applicable laws in the United States, India, or in the jurisdiction of purchase. The products and services offered are the intellectual property of AMR, and are protected by applicable copyright laws, international treaty provisions, and other applicable laws of the country in which these are being used. Albeit the abovementioned, you are NOT be permitted to:

transmit or permit any third party to use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to assign the rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial/noncommercial gains

share the information or content either electronically or in printed form with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization or any other unauthorized users.

 

Five-User License:

This  grants up to Five non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online. The right to store, transfer, display, use, or stockpile the report is restricted to only FIVE authorized users. An individual representing an organization or an organization shall ONLY purchase the five-user license. The authorized users can print additional duplicate printed copies of the report for distribution to the employees of his/her company (Personnel). Albeit the abovementioned, you are NOT be permitted to:

 

transmit or permit by any means to any third party (i.e. non-personnel) or unauthorized users for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer, or attempt to redistribute or assign rights of the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use, or store the content from the report other than for internal business purposes; exclusively permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

take photocopies, share with non-authorized users, and/or copy content from this publication to further distribute for commercial or noncommercial gains.

share the information or content either electronically or as printed copies with fellow-mates, public libraries, researchers, lecturers, college, university, foundation, government agency, corporate, non-profit organization, or to more than 5 AUTHORIZED USERS.

 

Enterprise License:

This  grants global, non-exclusive, non-transferable machine-readable licenses for using the report either electronically or online, within the organization and/or its subsidiaries. The authorized users shall have complete right to store, display, transfer, and/or use the report ONLY within the organization or its subsidiaries. Authorized users can take unlimited printed copies of the report for distribution among its employees. Albeit the abovementioned, you shall NOT be permitted to:

transmit or permit by any means to any third party (i.e. non-personnel) for use and/or gain access to the report;

resell, sub-license, rent, lease, transfer or attempt to assign the rights in the report (in whole or in part) to any party NOT authorized by AMR;

modify, alter, create database, broadcast, communicate, transfer, pledge, rent, reproduce, transmit, display, copy, distribute, commercially exploit, use or store the content from the report other than for internal business purposes; expressly permitted above; and

use the report in any comportment that would breach the terms and conditions contained in these License Terms or that would violate the applicable laws in the United Sates, India, or in any other jurisdiction.

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

Allergan plc., AstraZeneca plc., Bayer AG, Bristol-Myers Squibb Company, Johnson and Johnson, Mylan N.V., Novartis AG, Pfizer Inc., SANOFI, and Teva Pharmaceutical Industries.